AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00980174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg denosumab
Description: 60 mg denosumab (SC injection every 6 months)
Study NCT00980174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 60 mg denosumab
Description: 60 mg denosumab (SC injection every 6 months)
Study NCT00980174 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for denosumab (SC injection every 6 months)
Study NCT02747797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: 10 mg orally daily
Study NCT04588727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3366
Description: In Part A, subjects will be randomized to receive intravenous infusion AZD3366 dose 1-7, single ascending dose (SAD). In Part A, Dose 2-7 may be adjusted based on PK data from previous cohort\[s\]. In Part B, subjects will be randomized to receive intravenous infusion AZD3366 dose X (a dose resulting in predicted therapeutic exposure).
Study NCT03772041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-61815
Description: Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg
Study NCT03772041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan Tab 15 MG
Description: Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo
Study NCT02271685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions about Overestimates
Description: Participants are told that overestimating the duration of sounds are associated with low disease risk.
Study NCT02271685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions about Parkinson's
Description: Participants are told that the task is about risk of Parkinson's disease.
Study NCT02271685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions about Underestimates
Description: Participants are told that underestimating the duration of sounds are associated with low disease risk.
Study NCT02271685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instructions about Alzheimers
Description: Participants are told that the task is about risk of Alzheimers disease.
Study NCT00703105 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccination
Description: DC vaccination with 1 x 10(6th) tumor lysate or tumor peptides and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals; (6 weeks)
Study NCT03371485 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AST-VAC2
Description: Allogeneic dendritic cell vaccine.
Study NCT02723305 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT04061863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 360mg on D1 every 3 weeks Eribulin 1.4mg/m2 on D1, 8 every 3 weeks
Study NCT02737202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject will have visits every 90 days for drug accountability as well as safety and efficacy testing to include pulmonary function testing, laboratory testing to include liver and kidney profile, urine pregnancy testing at each visit, vital signs, physical examination - any medically significant changes from baseline visit will be recorded, all adverse events will be monitored until resolution.
Study NCT02236598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K+ supplement
Study NCT02236598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03140449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24).
Study NCT03140449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24).
Study NCT03140449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin-calcitriol combination
Description: topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24).
Study NCT06123364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirabegron 50 mg daily
Description: Patients in both study groups will receive 50 mg of mirabegron daily in the form of tablets, which is used to treat OAB according to current treatment guidelines.
Study NCT06123364 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: mirabegron 50 mg daily
Description: Patients in both study groups will receive 50 mg of mirabegron daily in the form of tablets, which is used to treat OAB according to current treatment guidelines.
Study NCT06123364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal magnetic innervation (active treatment)
Description: Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive sham stimulation.
Study NCT06123364 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Extracorporeal magnetic innervation (sham treatment)
Description: Patients will twice a week receive extracorporeal electromagnetic stimulation in the duration of 20 minutes. Patients will be randomized into 2 study groups, namely one group will receive actual electromagnetic stimulation, and the other group will receive placebo stimulation.
Study NCT01484314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: 100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy
Study NCT03044002 — intervention group
Intervention type: DEVICE
Intervention: Biotronik 4 French Portfolio
Description: Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
Study NCT03044002 — intervention group
Intervention type: DEVICE
Intervention: 6 French Portfolio
Description: Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
Study NCT04613622 — intervention group
Intervention type: DRUG
Intervention: Venetoclax
Description: This prospective study will draw blood from every patient to measure the venetoclax blood concentration. After blood concentration analysis by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), the investigator will report the concentration to clinicians.
Study NCT02981537 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: two-staged endobronchial blocker insertion
Description: positioning endobronchial blockers in two-staged method
Study NCT02981537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: two-staged endobronchial blocker insertion
Description: positioning endobronchial blockers in two-staged method
Study NCT02981537 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single-staged endobronchial blocker insertion
Description: positioning endobronchial blockers in traditional single-staged method
Study NCT02981537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-staged endobronchial blocker insertion
Description: positioning endobronchial blockers in traditional single-staged method
Study NCT02381652 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cingal
Description: Injection into the knee
Study NCT04367363 — intervention group
Intervention type: BEHAVIORAL
Intervention: Social media & news consumption
Description: Daily reports of social media use and consumption, including reports on receiving and disseminating news articles related to the COVID-19 situation (e.g., how many messaging groups shared news on the outbreak, how many items related to the outbreak they forwarded to others, etc).
Study NCT02125136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gem/nab-Pac
Description: All patient receive:~2 cycles gemcitabine/nab-paclitaxel (\[Gem/nab-Pac\]; duration of each cycle 28 days)~Then:~Nab-paclitaxel 125 mg/m2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m2 as a 30-minute IV infusion on D1, D8, D15 of each 28-day cycle
Study NCT02125136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIFINOX
Description: All patient receive:~2 cycles gemcitabine/nab-paclitaxel (\[Gem/nab-Pac\]; duration of each cycle 28 days)~Then:~Oxaliplatin 85 mg/m2, given as a 2-hour intravenous infusion D1 Folinic acid 400 mg/m2, given as a 2-hour intravenous infusion D1 Irinotecan 180 mg/m2, given as a 90-minutes intravenous infusion D1 (application through a Y-connector parallel to infusion of folinic acid or 30 minutes after start of folinic acid possible) Fluorouracil 400 mg/m2, administered by intravenous bolus, followed by a continuous intravenous infusion of fluorouracil 2400 mg/m2 over a 46-hour period D1.~To be repeated on D1 of each cycle.
Study NCT01593865 — intervention group
Intervention type: PROCEDURE
Intervention: BIMA Grafting
Description: Both the left and the right internal mammary arteries are harvested and used to revascularize the two major coronary targets. Further coronary targets may be revascularized using either great saphenous vein or radial artery grafts, if present.
Study NCT01593865 — intervention group
Intervention type: PROCEDURE
Intervention: Left-only mammary artery grafting
Description: These patients had only the left mammary artery harvested and used to revascularize the major coronary target. Great saphenous vein grafts and/or radial artery grafts were employed to revascularize the remaining targets.
Study NCT04310683 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: natural cycle for endometrium preparation
Description: patients will not use oral contraceptive drugs
Study NCT04310683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hormone replaced cycle for endometrium preparation
Description: patients will receive oral contraceptive drugs for menstruation before embryo transfer
Study NCT02205541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28. According to the length of initial hospital stay, patients may have the remaining injections in the day ward of the recruiting center. Dosage of ECZ will be based on previous trials using ECZ in pediatric aHUS patients.~ECZ or placebo will be administrated intravenously as a 30-minute injection
Study NCT02205541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28.~ECZ or placebo will be administrated intravenously as a 30-minute injection
Study NCT02696863 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire
Study NCT02115334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: professional therapists delivering the PHPA
Description: PHPA are delivered by professional therapists, which including gross motor, fine motor, cognition verbal, social interactions, activity of daily living(ADL).
Study NCT04588727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Part A and Part B, subjects will be randomized to receive intravenous infusion of placebo (0.9% sodium chloride solution).
Study NCT04588727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: In Part B, subjects will receive oral ticagrelor tablets.
Study NCT04588727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ticagrelor
Description: In Part B, subjects will receive oral ticagrelor tablets.
Study NCT04588727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid (ASA)
Description: In Part B, subjects will receive oral ASA chewable tablets.
Study NCT04588727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetylsalicylic acid (ASA)
Description: In Part B, subjects will receive oral ASA chewable tablets.
Study NCT02645552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid 1 gram in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
Study NCT02645552 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: Sodium Chloride solution (0.9%) 1 ml (gram) in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
Study NCT04940520 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Drug recommended by the Brazilian Society of Dermatology
Description: Using a drug recommended by the Brazilian Society of Dermatology, twice a day.
Study NCT04940520 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Alpha bisabolol product and laser
Description: Using alpha bisabolol-based product associated with low-level laser therapy. Alpha bisabolol-based product will be used twice a day, and laser therapy used once every fortnight.
Study NCT04940520 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Alpha bisabolol product
Description: Using alpha bisabolol-based product twice a day
Study NCT00334802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Phase 1: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles (dose escalation)~Phase 2: dose determined by phase 1
Study NCT00334802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Phase 1: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles~Phase 2: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles
Study NCT04840459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAMLANIVIMAB
Description: n. Bamlanivimab is a recombinant neutralizing human mIgG1? monoclonal antibody (mAb) to the spike protein of SARS-CoV-2, and is unmodified in the Fc region.
Study NCT04840459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CASIRIVIMAB
Description: CASIRIVIMAB is a recombinant human mAbs which are unmodified in the Fc regions.
Study NCT04840459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMDEVIMAB
Description: IMDEVIMAB is a recombinant human mAbs which are unmodified in the Fc regions.
Study NCT06173739 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical mechanical treatment
Description: Nonsurgical mechanical therapy (NSMT) aims to control infection and minimize bacterial burden through debridement of the implant surface. It is the gold standard treatment method for both peri-implantitis and peri-implant mucositis.~Non-surgical mechanical treatment will be applied to patients with the purpose of surface debridement and reducing bacterial flora in implants with peri-implant disease for which clinical examination has been completed and the diagnosis has been confirmed. All intraoral implants of the patients will be evaluated and all implants that do not meet the clinical definition of health will be intervened. Each implant surface will be treated with a titanium curette. In all groups, mechanical debridement was performed on the surfaces by the same clinician.~The procedure will continue gently until it is felt that it has been adequately debrided. Subgingival irrigation will be performed with physiological saline. Post NSMT No medication will be administered.
Study NCT00432315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + CDDP
Description: * 3 cycles chemotherapy : docetaxel + CDDP~* Surgery (if no histologically proven R0-resection could be achieved,additional adjuvant radiotherapy should be considered)~* 3 cycles adjuvant chemotherapy docetaxel
Study NCT00432315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel + CDDP
Description: * 3 cycles chemotherapy: docetaxel + CDDP~* Radiochemotherapy~* 3 cycles adjuvant chemotherapy docetaxel
Study NCT02811497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study NCT02811497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Study NCT01746238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous infusion, every 2 weeks, 3 doses total
Study NCT01746238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Intravenous infusion, bolus infusion followed by 4 day continuous infusion, every week for 5 weeks
Study NCT01746238 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Daily, Monday-Friday, for 6 weeks
Study NCT01350440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVIG
Description: Intravenous Immune Globulin
Study NCT01346540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: VEGF inhibitor
Study NCT01346540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BIBF 1120 placebo
Study NCT00110916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-articular metHuIL-1ra (anakinra)
Description: anakinra
Study NCT00110916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT05771818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Falls Prevention Program
Description: The intervention consists of 10 sessions. One session a week consists of obstacle course training. The other session focuses on falls strategies training and walking and balance exercises. Each session lasts approximately 1.5 hours.
Study NCT03747302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Media Message about HPV and HPV vaccine
Description: Messages educate parents with facts about HPV vaccination.
Study NCT03747302 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Social media message about risk of electronic cigarettes.
Description: Messages educate parents with facts about electronic cigarettes. This is an attention control group without outcomes obtained.
Study NCT01714609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: Placebo
Study NCT01714609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib, 400 mg twice daily
Study NCT02172040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Over-encapsulated 10 mg amlodipine besylate tablet
Description: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks
Study NCT02115334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parents executing the PHPA
Description: PHPA are executed by parents, which including gross motor, fine motor, cognition verbal, social interactions, ADL.
Study NCT02115334 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health education
Description: health education of the children with DD.
Study NCT03047902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 - Parents will be present for the Questionnaire.
Description: In Group 1 the parents will be present for the questionnaire. The information on the questionnaire will be disclosed to them.~In Group 2 the parents will not be present for the questionnaire and the information will not be disclosed to them.
Study NCT03047902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2- Parents will not be present for the Questionnaire
Study NCT01099683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001
Description: Single rectal administration of 2 mg NRL001 in a 2 g suppository
Study NCT01099683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects will receive rectal suppository containing placebo
Study NCT03305471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2330b PIB
Description: DS-2330b as powder in bottle with stock solution (PIB)
Study NCT02172040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Over-encapsulated 10 mg amlodipine besylate tablet
Description: Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks
Study NCT02172040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matched placebo capsule for over-encapsulated celecoxib capsule
Description: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
Study NCT02172040 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Matched placebo capsule for over-encapsulated celecoxib capsule
Description: Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
Study NCT02172040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Over-encapsulated 200 mg celecoxib capsule
Description: Over-encapsulated 200 mg celecoxib capsule once a day for two weeks